Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of OAB (frequency/urgency) with urinary incontinence for at least 6 months~* Inadequate response or limiting side effects with anticholinergics for the treatment of OAB~Exclusion Criteria:~* Overactive Bladder caused by neurological condition~* Patient has predominance of stress incontinence~* History or evidence of pelvic or urological abnormality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- onabotulinumtoxinA (Type: EXPERIMENTAL): OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
- placebo/onabotulinumtoxinA (Type: OTHER): Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).

Based on this trial design, predict the completion outcome and termination type (if applicable).